A ‘healthy’ processed food to normalise and maintain blood sugar levels in individuals at risk of Type-II Diabetes

该项目将为饮食干预提供关键数据，以降低被定义为“糖尿病前期”的人的空腹血糖（FBG）水平。这种简单的饮食解决方案有可能对ii型糖尿病（T2D）的发病率产生重大影响，这是英国乃至全世界一个主要且日益严重的问题：据估计，英国有1500万糖尿病前期患者，400万糖尿病前期患者，全球有超过10亿糖尿病前期患者和3.7亿糖尿病患者。仅糖尿病处方每年就花费NHS超过10亿英镑。因此，这个项目处理的是一个非常重要的公共卫生问题，这方面有巨大的和不断增长的市场机会。一项为期两年的关于饮食和前列腺癌的研究数据显示，使用我们的专利汤产品的个体将高于正常水平的血糖降低到与健康相关的水平，并在试验期间保持在这个较低的水平。这种效果是通过每周只喝一份300毫升的汤来实现的，没有其他饮食或生活方式的改变。降低血糖并不是这项研究的主要终点，需要进行更大规模的研究，特别关注我们的食品对血糖的影响。智能食品公司（TSFC）的成立是为了开发这项技术，并将有助于血糖管理的食品推向市场。TSFC正在寻求UKI2S加速器资金，由私人投资配合，进行一项临界规模和设计的人体试验，以测试一份汤能将糖尿病前期患者的血糖降至“健康”水平的假设。这种汤是由一种独特的、专有的西兰花制成的，这种西兰花自然繁殖，含有高浓度的葡萄糖苷（VHG）。这个汤将被用来验证最初的发现，并确认葡萄糖苷在提供预期效果方面的作用。试验的成功结果将撬动大量私人投资，将该产品以及未来的产品推向市场。这些食品将销售给糖尿病前期患者、参与筛查、监测和治疗糖尿病的卫生保健专业人员、糖尿病慈善机构和其他相关非政府组织、有健康意识和担忧的人，并具有欧洲食品标准局（EFSA）批准的健康声明，以及其他市场的同等产品。这些产品将通过主要的食品零售商和直接在线销售。

This project will secure critical data for a dietary intervention to reduce fasting blood glucose (FBG) levels in people who are defined as being 'pre-diabetic'. A simple dietary solution of this nature has the potential to have a significant impact on the incidence of type-II diabetes (T2D), a major and growing problem in UK and throughout the world: it is estimated that there are 15m pre-diabetic people in the UK and 4m with T2D and globally over 1bn pre- diabetic and 370m diabetic. Diabetes prescriptions alone cost the NHS over £1bn every year. Therefore, this project addresses a public health issue of great importance, and for which there are large and growing market opportunities.Data from a two-year study on diet and prostate cancer with our proprietary soup product showed that individuals had a reduction in their higher-than- normal blood glucose to levels associated with good health, and remained at this lower level for the duration of the trial. This effect was achieved by consuming just one 300ml portion of soup per week, with no other changes to diet or lifestyle. Blood glucose reduction was not the primary endpoint of this study, and a larger study is needed that is specially focussed on the effect of our food product on blood glucose.The Smarter Food Company (TSFC) has been established to develop this technology and bring to market food products that will assist in the management of blood glucose. TSFC is seeking UKI2S Accelerator funding, matched by private investment, to undertake a human trial of a critical size, and design, to test the hypothesis that a single portion of soup will reduce blood glucose in pre-diabetic individuals to 'healthy' levels. The soup is manufactured from a unique and proprietary broccoli naturally bred to contain very high concentrations of glucoraphanin (VHG). This soup will be used to validate the original findings and confirm the role of glucoraphanin in delivering the desired effect. The successful outcome of the trial will lever substantial private investment to bring this product to market as well as future products. These foods will be marketed to pre-diabetics, health care professionals involved with screening, monitoring and treating T2D, diabetes charities and other relevant NGOs, the health-conscious and worried well, with an approved European Food Standards Agency (EFSA) health claim, and equivalent for other markets. The products will be sold through the major food retailers and by direct online sales.